Drug Profile
Research programme: cytokine synthesis inhibitors - Angelini
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Angelini Group
- Class
- Mechanism of Action Chemokine CCL2 inhibitors; Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer; Inflammatory bowel diseases; Inflammatory pain; Neuropathic pain; Prostate cancer; Uveitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in Italy
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Italy
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-pain in Italy